All lobbying filings

MEHLMAN CONSULTING, INC.

MEHLMAN CONSULTING, INC. filed a Q2 report for ULTRAGENYX PHARMACEUTICAL, INC. on July 20, 2026, reporting $60,000 in lobbying income.

Lobbying for ULTRAGENYX PHARMACEUTICAL, INC. · Biopharmaceutical Company

All filings by MEHLMAN CONSULTING, INC. · Everything ULTRAGENYX PHARMACEUTICAL, INC. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues relating to rare disease and patient access.

Budget/Appropriations

FY27 Appropriations (H.R.8646, Agriculture, Rural Development, Food and Drug Administration)

Bills named in this filing 1

H.R. 8646
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.